====== Sudeep Gill ======

{{ ::gill_sudeep_2019.jpeg?200|}}

Dr. **Sudeep S. Gill**, MD MSc FRCPC is a Canadian geriatrician and health services researcher based in [[canada:Ontario:Kingston]], [[canada:Ontario]].

===== Career and Affiliations =====

==== Queen's University ====

Gill is an associate professor in the Division of Geriatric Medicine, with cross-appointment in the Department of Public Health Sciences in the Department of Medicine at [[Queen's University]].((//Gill | Department of Medicine | School of Medicine.// Queen’s University. Retrieved May 5, 2022, from https://archive.ph/zYmh6))

He he has been a member of Senate Advisory Research Committee (2009-2012), a member of the AHSC AFP Innovation Fund grant application review committee, and a member of the Department of Medicine Promotions Committee.
==== ICES ====

Gill is a senior adjunct scientist at the [[Institute for Clinical Evaluative Sciences]] (ICES).((//Sudeep Gill.// Institutes for Clinical Evaluative Sciences. Retrieved May 6, 2022, from https://www.ices.on.ca/About-ICES/ICES-Scientists/G/Sudeep-Gill))

==== Clinical Work ====

Gill works in Specialized Geriatrics services at [[Providence Care]] (inpatient geriatric rehabilitation and outpatient geriatric medicine clinics) and [[Kingston Health Sciences Centre|Kingston General Hospital]] (geriatrics consult service).((//Doctor Gill, Sudeep S - Geriatric Medicine.// (2021, August 13). South East Local Health Integration Network. https://archive.ph/iwdoG)) He previously served as Chair of the Providence Care Pharmacy and Therapeutics Committee.

Both facilities raise money through the [[University Hospitals Kingston Foundation]], including from a variety of [[pharmaceutical companies]].((//Recognizing Your Contribution.// Kingston University Hospital Foundation. Retrieved May 4, 2022, from https://web.archive.org/web/20220504073124/https://www.uhkf.ca/Your-Impact/Recognizing-Your-Contribution))

==== Government of Ontario ====

Gill has been a member of the [[Committee to Evaluate Drugs]] (CED), an advisory committee to the [[Ontario Ministry of Health and Long-Term Care]] on decisions about medications included on the province’s publicly funded formulary.

==== Ontario COVID-19 Science Advisory Table ====

Gill is a member of the Congregate Care Setting Working Group of the [[Ontario COVID-19 Science Advisory Table]].((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved April 28, 2022, from https://covid19-sciencetable.ca/about/))

===== Research =====

==== Funding ====

Gill has co-authored research that was funded by the [[Canadian Lung Association]].((Vozoris, N. T., Pequeno, P., Li, P., Austin, P. C., Stephenson, A. L., O’Donnell, D. E., Gill, S. S., Gershon, A. S., & Rochon, P. A. (2021). //Morbidity and mortality associated with prescription cannabinoid drug use in COPD.// Thorax, 76(1), 29–36. https://doi.org/10.1136/thoraxjnl-2020-215346)) The CLA is partnered with [[Immunize Canada]] and funded by [[pharmaceutical_companies:Actelion]], [[pharmaceutical_companies:AbbVie]], [[AllerGen]], [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Bayer]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[GE Healthcare]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Grifols]], [[pharmaceutical_companies:Hospira]], [[pharmaceutical_companies:Intermune]], [[medical_technology_companies:ManthaMed]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Novartis]], [[pharmaceutical_companies:Pediapharm]], [[pharmaceutical_companies:Pfizer]], [[medical_technology_companies:ProResp]], [[pharmaceutical_companies:Roche]], [[pharmaceutical_companies:Takeda]], [[pharmaceutical_companies:Teva]], [[medical_technology_companies:Trudell Medical]], [[pharmaceutica;_companies:Unither Biotech]] and [[pharmaceutical_companies:Vertex]].((//About Us.// (2016, December 10). Canadian Lung Association. https://archive.ph/XNGx1)) ((//2020/2021 Annual Report.// Canadian Lung Association. Retrieved May 5, 2022, from https://web.archive.org/web/20220505235346/https://www.lung.ca/sites/default/files/LungAssociation_AnnualReport_2020_2021_EN_FIN.pdf)) ((//2019/2020 Annual Report.// Wayback Machine; Canadian Lung Association. Retrieved May 5, 2022, from https://web.archive.org/web/20220505235859/https://www.lung.ca/sites/default/files/LungAssociation_AnnualReport_2019_2020_EN.pdf)) ((//2017-2018 Annual Report.// Canadian Lung Association. Retrieved May 6, 2022, from https://web.archive.org/web/20220506181857/https://www.lung.ca/sites/default/files/CLA_AnnualReport2017_2018_EN_FINALSEPT21.pdf)) ((//2015/2016 Annual Report.// Canadian Lung Association. Retrieved May 6, 2022, from https://web.archive.org/web/20220506182758/https://www.lung.ca/sites/default/files/LungAssociation_AnnualReport_2015_2016_EN.pdf)) ((//2014/2015 Annual Report.// Canadian Lung Association. Retrieved May 6, 2022, from https://web.archive.org/web/20160413195706/http://www.lung.ca/file/1172/download?token=B8JBiFLw))